环吡酮胺(Ciclopirox olamine) - 在研适应症：外阴阴道念珠菌病，脂溢性皮炎，真菌病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Ciclopirox Olamine Cream、Ciclopirox Olamine Gream、Ciclopirox Olamine Vaginal Suppositories

+ [13]

靶点-

作用方式-

作用机制-

治疗领域

感染皮肤和肌肉骨骼疾病泌尿生殖系统疾病+ [2]

在研适应症

外阴阴道念珠菌病脂溢性皮炎真菌病+ [2]

非在研适应症

足癣

原研机构

Medimetriks Pharmaceuticals, Inc.

在研机构

Kafrelsheikh University

湖北科田药业有限公司

Lsu Health Shreveport

+ [1]

非在研机构

Perrigo Co. Plc

权益机构-

最高研发阶段批准上市

首次获批日期

中国 (1989-01-01),

外阴阴道念珠菌病脂溢性皮炎真菌病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C14H24N2O3

InChIKeyMBRHNTMUYWQHMR-UHFFFAOYSA-N

CAS号41621-49-2

查看全部结构式(2)

关联

11

项与环吡酮胺相关的临床试验

NCT05647343

/ Completed临床1期

A Phase I, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers

开始日期2023-03-31

申办/合作机构

Atlas Molecular Pharma SL

CTRI/2022/01/039543

/ CompletedN/A

Evaluation of Skin Safety of a test product Ciclopirox Olamine Cream USP 1percent w/w for Primary Skin Irritation Using Skin lrritation Test (Patch Test in Humans) IS 4011 2018 Guidelines

开始日期2022-01-21

申办/合作机构

Cipla Ltd.

EUCTR2018-001633-41-DE

/ Not yet recruiting临床3期

Double-blind, randomised clinical study comparing efficacy and safety of Ciclopirox Olamine Cream 10 mg/g (Test) vs. Batrafen® Cream (Reference) vs. Vehicle in patients with skin mycoses

开始日期2019-06-18

申办/合作机构

Dermapharm AG

100 项与环吡酮胺相关的临床结果

登录后查看更多信息

100 项与环吡酮胺相关的转化医学

登录后查看更多信息

100 项与环吡酮胺相关的专利（医药）

登录后查看更多信息

871

项与环吡酮胺相关的文献（医药）

2025-02-01·Mycopathologia

Whole Genome Sequence Analysis of Terbinafine Resistant and Susceptible Trichophyton Isolates from Human and Animal Origin

Article

作者: Chakrabarti, Arunaloke ; Meijer, Eelco F J ; de Groot, Theun ; Dogra, Sunil ; Abhishek ; Thakur, Sheetal ; Spruijtenburg, Bram ; Shaw, Dipika ; Rudramurthy, Shivaprakash M ; Narang, Tarun ; Meis, Jacques F

Trichophyton indotineae, first identified in India, has increasingly been reported in Asia, the Middle East, Europe, and recently in the USA. The global spread of terbinafine-resistant T. indotineae underscores the urgency of the issue. With its ability for human-to-human transmission, it can be considered anthropophilic. However, its highly virulent nature suggests a possible link to zoophilic species, raising the potential for disease transmission from animals. In this study, we have performed whole genome sequencing (WGS) of terbinafine susceptible and resistant Trichophyton species from animal and human origin to understand transmission dynamics of this species. Thirteen isolates of Trichophyton spp. from human (n = 9) and canine (n = 4) origin, respectively from Chandigarh and Bareilly, India, were included in this study. Isolate identification based on ITS extracted from WGS data identified six T. indotineae (ITS genotype VIII) and seven T. interdigitale (ITS genotype II) isolates. WGS single nucleotide polymorhpism (SNP) analysis separated the isolates into two distinct groups, T. indotineae and T. interdigitale and showed the clonal nature of both species. For both species, low SNP differences between isolates from humans and dogs were observed as well as low differences between isolates from Chandigarh and Bareilly, cities >350 km apart from each other. These findings suggest zoonotic transmission, next to fast spread across large distances. The T. indotineae terbinafine-resistant strains exhibited the SQLE^F397L substitution while susceptible strains had the SQLE^S395P substitution or demonstrated a wild-type (WT) SQLE sequence. However, all T. interdigitale strains displayed a WT SQLE sequence despite terbinafine minimum inhibitory concentrations (MICs) ranging between 0.031 to 64 µg/mL.

2025-02-01·Journal of Molecular Structure

Expanding the potential of pyridine scaffold for targeted therapy of cancer: Biological activity, molecular insights, and structure-activity relationship

作者: Hosamani, Ketan R ; I, Aayishamma ; Aishwarya, Nimmagadda Venkata Satya Sai ; B, Kumaraswamy ; BV, Manjushree ; Ghara, Abhishek ; Pal, Rohit ; Hosamani, Ketan R. ; Bv, Manjushree ; Matada, Gurubasavaraja Swamy Purawarga

A review.Pyridine-based ring structures are widely employed in drug design due to their significant impact on pharmacol. activity, resulting in the development of various broad-spectrum therapeutics.The US FDA approves 95 pharmaceuticals derived from pyridine, including isoniazid and ethionamide for tuberculosis, delavirdine for HIV/AIDS, abiraterone acetate for prostate cancer, tacrine for Alzheimers, ciclopirox for ringworm and athletes foot, crizotinib for cancer, nifedipine for Raynauds syndrome and premature birth, piroxicam for arthritis, and nilvadipine for hypertension.Moreover, pyridine derivatives act as an excellent candidate for targeted anticancer agents.However, pyridine anti-cancer therapies continue to encounter hurdles, including poor response rates and drug resistance.Researchers are exploring pyridine derivatives as a potential treatment for targeted anticancer therapies.To further the development of targeted anti-cancer therapies, we analyzed pyridine-targeted drugs based on target categorization.We have covered all researchers of the last six years (2019-2024) investigating pyridine derivatives as targeted anticancer treatments.The highlights of pyridine-containing drugs and their targets are listed, as well as most promising drug candidates in clin. trials containing pyridine are also discussed.This review also included explanatory insights and viewpoints from several groups involved in the creation of targeted anticancer pyridine derivatives, with an emphasis on the structure-activity relationship (SAR).We hope that the current review provides insights and perspectives for the research and development of pyridine-containing anti-cancer drugs.

2025-01-07·Proceedings of the National Academy of Sciences

ANAC044 orchestrates mitochondrial stress signaling to trigger iron-induced stem cell death in root meristems

Article

作者: Xiao, Yihui ; Yan, Juanmei ; Busch, Wolfgang ; Lin, Xianyong ; Zhou, Ming ; Zhao, Xiaobo ; Shi, Weiming ; Feng, Zhihang ; Li, Baohai

While iron (Fe) is essential for life and plays important roles for almost all growth related processes, it can trigger cell death in both animals and plants. However, the underlying mechanisms for Fe-induced cell death in plants remain largely unknown. S-nitrosoglutathione reductase (GSNOR) has previously been reported to regulate nitric oxide homeostasis to prevent Fe-induced cell death within root meristems. Here, we found that in the absence of GSNOR , exposure to high Fe treatment results in DNA damage–dependent cell death specifically in vascular stem cells in root meristems within 48 h. Through a series of time-course transcriptomic analyses, we unveil that in the absence of GSNOR , mitochondrial dysfunction emerges as the most prominent response to high Fe treatment. Consistently, the application of mitochondrial respiratory inhibitors leads to stem cell death in root meristems, and pharmacological blockage of the voltage-dependent anion channel that is responsible for the release of mitochondrial-derived molecules into the cytosol or genetic changes that abolish the ANAC017- and ANAC013-mediated mitochondrial retrograde signaling effectively eliminate Fe-induced stem cell death in gsnor root meristems. We further identify the nuclear transcription factor ANAC044 as a mediator of this mitochondrial retrograde signaling. Disruption of ANAC044 completely abolishes the GSNOR-dependent, Fe-induced stem cell death in root meristems, while ectopic expression of ANAC044 causes severe root stem cell death. Collectively, our findings reveal a mechanism responsible for initiating Fe-induced stem cell death in the root meristem, which is the ANAC044-mediated GSNOR-regulated mitochondrial stress signaling pathway.

100 项与环吡酮胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01364	环吡酮胺	D01AE14 G01AX12	DBSALT001147

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
外阴阴道念珠菌病	中国	湖北科田药业有限公司	1989-01-01
脂溢性皮炎	中国	湖北科益药业股份有限公司	1989-01-01
真菌病	中国	湖北科田药业有限公司	1989-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床前	埃及	Kafrelsheikh University	2024-10-07
肿瘤	药物发现	美国	Lsu Health Shreveport	2012-04-15
足癣	药物发现	-	Perrigo Co. Plc	2003-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2019	N/A	多囊肾	-	Ciclopirox-Olamine	選鏇餘鏇願淵製襯鹽襯(繭鬱憲壓獵齋壓夢壓艱) = 網糧積壓鹹鏇製鑰簾窪壓衊襯鏇艱鬱獵簾積鬱 (窪淵積築夢糧膚艱廠選 ) 更多	积极	2019-11-05
NCT00804193 (CTgov)	N/A	足癣	553	Ciclopirox Olamine Topical Suspension (Test Product)	醖築繭壓憲夢廠淵鏇淵(範衊淵膚憲窪鏇夢繭簾) = 膚醖醖憲鹹繭獵襯構選鑰簾構鹽範願憲蓋糧獵 (範鏇淵鹽鏇築夢壓艱鹽, 壓襯醖蓋襯壓選遞積衊 ~ 鏇選醖獵築築淵製壓繭) 更多	-	2012-12-17
				Ciclopirox Topical Suspension 0.77%-Reference Product (Reference Product)	醖築繭壓憲夢廠淵鏇淵(範衊淵膚憲窪鏇夢繭簾) = 範蓋積積膚齋繭鑰範齋鑰簾構鹽範願憲蓋糧獵 (範鏇淵鹽鏇築夢壓艱鹽, 窪壓製獵襯願餘夢艱願 ~ 襯憲鬱壓顧獵窪蓋鏇糧) 更多
NCT00802672 (CTgov)	临床3期	足癣	561	Ciclopirox Olamine Cream (Test Product)	窪簾廠積鹹遞顧繭襯鏇(構衊鬱衊壓襯廠鬱廠醖) = 獵鹹範壓顧鏇壓鑰鏇製鏇淵鹹簾鑰夢鬱壓選壓 (糧齋築淵壓鑰範襯構鏇, 鬱鏇鏇窪觸願壓襯憲衊 ~ 顧遞築艱觸觸網糧夢醖) 更多	-	2012-06-19
				Loprox Cream 0.77% (Reference Product)	窪簾廠積鹹遞顧繭襯鏇(構衊鬱衊壓襯廠鬱廠醖) = 醖衊蓋積繭築襯鑰膚鹽鏇淵鹹簾鑰夢鬱壓選壓 (糧齋築淵壓鑰範襯構鏇, 衊醖憲願網獵鬱鹹鏇繭 ~ 膚鹽選鹽襯觸積膚遞製) 更多